KRAS and pancreatic ductal adenocarcinoma: Crucially, loss of YAP in the pancreas inhibits the development of pancreatic ductal adenocarcinoma in a genetically-engineered Kras mouse model [111], implying that YAP is a promising target for cancers harboring activating mutations in KRAS. Finally, YAP can also be overexpressed as a form of escape mechanism from oncogenic KRAS addiction in pancreatic cancer.